A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, MulticenterProtocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn's Disease
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2018
At a glance
- Drugs JNJ 64304500 (Primary) ; Ustekinumab
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms TRIDENT
- Sponsors Janssen Research & Development
- 31 Oct 2017 Planned End Date changed from 6 Aug 2020 to 16 Oct 2020.
- 03 Oct 2017 Planned End Date changed from 6 Aug 2017 to 6 Aug 2020.
- 03 Oct 2017 Planned End Date changed from 24 Jun 2020 to 6 Aug 2017.